Drug Profile

CIN 209

Alternative Names: CIN-209

Latest Information Update: 28 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen Sciences Ireland UC
Developer CinFina Pharma
Class Obesity therapies
Mechanism of Action Glucagon-like peptide-1 receptor agonists; Growth differentiation factor 15 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2025 No recent reports of development identified for preclinical development in Obesity in USA (Parenteral, Injection)
30 May 2024 CinRx Pharma announces intention to submit IND to US FDA for Obesity
22 Sep 2021 CinFina Pharma in-licenses CIN 209 form Janssen Sciences Ireland for the treatment of Obesity

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com